GlucoTrack financials
$1.74−3.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.4M | -$4.2M | -$3.5M | -$4.3M | -$4.8M | -$3.5M | -$8.6M | -$3.3M | -$4.5M | -$3.0M | -$2.4M | -$2.2M |
| Net income | -$3.8M | -$4.3M | -$3.6M | -$4.2M | -$4.8M | -$6.8M | -$10.1M | -$5.1M | -$4.5M | -$2.9M | -$1.6M | -$2.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-11.40 | $-39.75 | $-59.08 | $-69.60 | $-144.30 | $-602.10 | $-8555.36 | $-16363.95 | $-14760.00 | $-10557.00 | $-3702.45 | $-8820.00 |
| EBITDA | -$3.4M | -$4.2M | -$3.5M | -$4.3M | -$4.8M | -$3.5M | -$3.9M | -$3.2M | -$4.5M | -$2.9M | -$2.4M | -$2.2M |
| Operating cash flow | -$3.6M | -$4.0M | -$3.9M | -$4.6M | -$3.7M | -$2.9M | -$3.5M | -$4.1M | -$1.9M | -$2.9M | -$2.4M | -$1.9M |
| Free cash flow | -$3.6M | -$4.0M | -$4.0M | -$4.7M | -$3.7M | -$2.9M | -$3.5M | -$4.2M | -$1.9M | -$3.0M | -$2.4M | -$1.9M |
| Diluted shares | 0.3M | 0.1M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.1M | $3.9M | $7.4M | $7.9M | $9.6M | $9.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $248.0K | $232.0K | $231.0K | $227.0K | $221.0K | $210.0K |
| Total assets | $1.5M | $4.4M | $7.8M | $8.3M | $10.2M | $9.6M |
| Total liabilities | $3.2M | $5.2M | $5.0M | $5.5M | $3.3M | $2.4M |
| Shareholders' equity | -$1.7M | -$851.0K | $2.8M | $2.8M | $6.9M | $7.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology